AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05179876
Drug: Macitentan
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.
Trial: NCT05179876
Drug: Selexipag
RxNorm normalized name: Selexipag
DrugBank: Selexipag (DB11362)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adult Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms (µg). Children with body weight category of \>=50 kg will use the tablets at the required dose strength as described for adults. Children with a body weight \< 50 kg will receive tablets for pediatric use (dose strengths: 100 and 150 mcg), twice daily to enable continuation of individually maximum tolerated dose of selexipag according to their body weight category.
Trial: NCT05419401
Drug: Capivasertib film-coated tablet, 200 mg
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg dose, oral, fasted
Trial: NCT06415175
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
Trial: NCT05593055
Drug: Potassium
RxNorm normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
Trial: NCT05652894
Drug: HX008
RxNorm normalized name: Immunoglobulin g4 (252-theronine,306-proline,432-alanine), anti-(human programmed cell death 1) (human-mus musculus monoclonal hx008 .gamma.4-chain), disulfide with human-mus musculus monoclonal hx008 .kappa.-chain, dimer
DrugBank: Pucotenlimab (DB17552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: HX008 200 mg ,Q3W
Trial: NCT06320990
Drug: Tamoxifen 20mg
RxNorm normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen is a nonsteroidal antiestrogen for oral administration.
Trial: NCT04597372
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.
Trial: NCT05949125
Drug: Allo-RevCAR01-T
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1.
Trial: NCT05353439
Drug: Tazemetostat Hydrobromide
RxNorm normalized name: tazemetostat hydrobromide
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05353439
Drug: Topotecan Hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05200247
Drug: spesolimab
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for infusion
Trial: NCT06328387
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.
Trial: NCT04951492
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04614909
Drug: Pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg administered orally BID for 4 days prior to surgical resection
Trial: NCT04614909
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg administered orally BID for 4 days prior to surgical resection
Trial: NCT04614909
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
Trial: NCT04897022
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed dose of pembrolizumab 200mg IV q3 weeks
Trial: NCT06089707
Drug: Naloxone Nasal Spray
RxNorm normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
Trial: NCT04677569
Drug: ALIS
RxNorm normalized name: Cialis
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation via nebulization over approximately 6 to 15 minutes
Trial: NCT04677569
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05355818
Drug: Delgocitinib
RxNorm normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cream for topical application
Trial: NCT05355818
Drug: Cream vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
Trial: NCT05294731
Drug: BGB-16673
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered
Trial: NCT05650723
Drug: Zanubrutinib Pill
RxNorm normalized name: zanubrutinib Pill
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg once per day by mouth
Trial: NCT05650723
Drug: Venetoclax Pill
RxNorm normalized name: venetoclax Pill
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
Trial: NCT05650723
Drug: Obinutuzumab Injection
RxNorm normalized name: obinutuzumab Injection
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000 mg IV given every 28 days
Trial: NCT05155007
Drug: Rilematovir
RxNorm normalized name: Rilematovir
DrugBank: Rilematovir (DB15672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilematovir will be administered orally as per assigned treatment sequence.
Trial: NCT05155007
Drug: Ciclosporin
RxNorm normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin will be administered orally as per assigned treatment sequence.
Trial: NCT04991311
Drug: Glepaglutide
RxNorm normalized name: Glepaglutide
DrugBank: Glepaglutide (DB14794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glepaglutide will be delivered in a single-use autoinjector.
Trial: NCT06580782
Drug: Calcium Carbonate 500 MG
RxNorm normalized name: calcium carbonate 500 MG
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate 500mg, orally, every 4 hours.
Trial: NCT06328387
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.
Trial: NCT06348173
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Compare the response to mepolizumab and benralizumab before and after treatment
Trial: NCT06328387
Drug: Trastuzumab Deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
Trial: NCT04523922
Drug: 40 IU Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
Trial: NCT05741164
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06581627
Drug: Etavopivat
RxNorm normalized name: Etavopivat
DrugBank: Etavopivat (DB18176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of Etavopivat will be administered in fasted state via oral route
Trial: NCT05618002
Drug: Lemborexant
RxNorm normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
Trial: NCT06090227
Drug: Metformin + Standard of Care
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
Trial: NCT06417892
Drug: PD-1inhibitor
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-1 antibody was selected according to first-line drug use
Trial: NCT06417892
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a small molecular anti-tumor angiogensis drug
Trial: NCT06417892
Drug: albumin paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a kind of cytotoxic chemotherapy drug
Trial: NCT05611710
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Anakinra~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)
Trial: NCT06072131
Drug: Belinostat Injection
RxNorm normalized name: belinostat Injection
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle
Trial: NCT04700709
Drug: Sirolimus Tab.
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/ml.
Trial: NCT06072131
Drug: Pralatrexate Injection
RxNorm normalized name: pralatrexate Injection
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle
Trial: NCT06072131
Drug: CHOP
RxNorm normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP is the comparator arm
Trial: NCT06072131
Drug: COP
RxNorm normalized name: COP
DrugBank: Creatinolfosfate (DB13071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COP is given in combination with Pralatrexate
Trial: NCT05398081
Drug: Cefuroxime (Zinnat®)
RxNorm normalized name: cefuroxime Oral Tablet [Zinnat]
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
Trial: NCT05398081
Drug: Ceftriaxone (Rocephin®)
RxNorm normalized name: ceftriaxone Injection [Rocephin]
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
Trial: NCT05720754
Drug: Diquafosol tetrasodium
RxNorm normalized name: diquafosol tetrasodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
Trial: NCT06581497
Drug: ICIs
RxNorm normalized name: bicisate
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.
Trial: NCT01931501
Drug: Torrent's Montelukast Sodium Chewable Tablets 5mg
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05428488
Drug: Abatacept (W12-W48)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study.
Trial: NCT05785754
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab injection
Trial: NCT05428488
Drug: TNF Inhibitor (W12-W48)
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
Trial: NCT06267118
Drug: Adrenaline
RxNorm normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dilute 0.3 ml adrenaline with 3 ml normal saline for nebulization
Trial: NCT05428488
Drug: TNF Inhibitor (W0-W12)
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
Trial: NCT05035836
Drug: Zanidatamab
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05035836
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05035836
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05347004
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 425809
Trial: NCT06788249
Drug: Ketamine only
RxNorm normalized name: Ketamine only product
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The primary study intervention involves the administration of intravenous ketamine (0.5 mg/kg) over a 40-minute infusion. Ketamine, an NMDA receptor antagonist, has shown rapid antidepressant effects in individuals with treatment-resistant depression.
Trial: NCT00002126
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06532799
Drug: Cyclophosphamid
RxNorm normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Trial: NCT06532799
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Trial: NCT06532799
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
Trial: NCT06532799
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion
Trial: NCT06638879
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a tacrolimus treatment via toothpaste application twice daily for three months.
Trial: NCT04289467
Drug: Fenfluramine
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label
Trial: NCT06238531
Drug: Gusacitinib
RxNorm normalized name: Gusacitinib
DrugBank: Gusacitinib (DB15670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An orally active dual SYK/JAK kinase inhibitor
Trial: NCT04796922
Drug: parsaclisib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
Trial: NCT04796922
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab will be administered intravenously on select days as per protocol.
Trial: NCT04796922
Drug: obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: obinutuzumab will be administered intravenously on select days as per protocol.
Trial: NCT06239298
Drug: Donafenib Tosilate Tablets
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
Trial: NCT05641935
Drug: Sulfur Hexafluoride Lipid Microspheres
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05281406
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg daily or reduced dose 40 mg daily
Trial: NCT05281406
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Trial: NCT05281406
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Trial: NCT05281406
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Trial: NCT06066359
Drug: Fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by (IV) vein
Trial: NCT06395038
Drug: Abatacept plus Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses
Trial: NCT05154487
Drug: Alpelisib Pill
RxNorm normalized name: alpelisib Pill
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kinase inhibitor
Trial: NCT05154487
Drug: Fulvestrant injection
RxNorm normalized name: Fulvestrant Injection
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: estrogen receptor agonist
Trial: NCT06228053
Drug: SX-682
RxNorm normalized name: SX-682
DrugBank: SX-682 (DB19210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose twice daily
Trial: NCT06228053
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose once daily
Trial: NCT05025241
Drug: NNZ-2591
RxNorm normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.